Breast Cancer and Triple-Negative Disease
Research activity includes HER2-positive breast cancer, triple-negative breast cancer, and oligometastatic breast cancer, with strong attention to neoadjuvant treatment, adjuvant therapy, and immune checkpoint inhibition. The portfolio also covers residual disease after systemic treatment and treatment strategies for metastatic breast cancer.
- HER2-targeted therapy
- Immunotherapy in TNBC
- Oligometastatic disease
- Residual disease management
Work in this area reflects interest in combining systemic agents with surgery and other local treatments for breast cancer subtypes with limited treatment options.
Gastrointestinal and Colorectal Cancer
The sponsor funds studies in colorectal cancer, metastatic colorectal cancer, colon cancer, rectal cancer, and gastric adenocarcinoma, including disease with peritoneal metastases or liver-limited spread. Additional interest extends to dMMR colorectal cancer and gastro-esophageal junction cancer.
- Peritoneal metastases
- Hepatic arterial infusion
- Hyperthermic intraperitoneal chemotherapy (HIPEC)
- Neoadjuvant immunotherapy
Clinical research in this domain also includes organ-preserving approaches and multimodal treatment strategies for locally advanced disease.
Urologic, Renal, and Prostate Cancer
Trials address urothelial carcinoma of the bladder, muscle-invasive bladder cancer, renal cell carcinoma, and prostate cancer, including metastatic castration-resistant prostate cancer and node-positive prostate cancer. The research also includes bladder-intact management and preoperative immunotherapy in urothelial and renal malignancies.
- Bladder cancer
- Renal cell carcinoma
- Prostate cancer
- Immunotherapy combinations
There is also interest in fertility-preserving and organ-sparing treatment pathways for selected urogenital cancers.
Head and Neck, Melanoma, and Skin Cancer
Research spans head and neck squamous cell carcinoma, oral cancer, tongue carcinoma, penile carcinoma, cutaneous squamous cell carcinoma, and melanoma, including stage II and stage III melanoma. Studies also examine sentinel node biopsy and organ preservation in tumors of the face, oral cavity, and related sites.
- Melanoma
- Head and neck cancer
- Sentinel node imaging
- Organ preservation
These activities show interest in combining local treatment planning with immunotherapy and image-guided surgical approaches.
Thoracic, Gynecologic, and Hematologic Malignancies
The research portfolio includes non-small cell lung cancer, brain metastases, pleural mesothelioma, ovarian cancer, cervical cancer, vulvar carcinoma, multiple myeloma, non-Hodgkin lymphoma, and T-cell prolymphocytic leukemia. Several studies focus on advanced solid tumors and metastatic disease across these specialties.
- Ovarian and cervical cancer
- Non-small cell lung cancer
- Hematologic malignancies
- Brain metastases
Within these areas, the sponsor is active in multimodal treatment, immuno-oncology, and surgery-linked approaches for locally advanced or recurrent disease.
